Biosimilars: Similarities to Enoxaparin and the Elephant in the Room
This article was originally published in RPM Report
FDA held a brief educational session on how it is approaching the biosimilars abbreviated pathway. In it, the agency’s Rachel Sherman touched on generic enoxaparin and how to track interchangeability.
You may also be interested in...
Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.
The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.